Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US

Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson
doi: https://doi.org/10.1101/2023.05.16.23289856
Todd G. Smith
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tgsmith1{at}cdc.gov
Crystal M. Gigante
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nhien T. Wynn
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Audrey Matheny
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Whitni Davidson
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Yang
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rene Edgar Condori
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle O’Connell
bOffice of Advanced Molecular Detection, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
cHealth Data and AI, Deloitte Consulting LLC, 1919 N. Lynn St, Arlington VA 22209
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynsey Kovar
bOffice of Advanced Molecular Detection, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
dLeidos Inc., Reston, VA 20190, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracie L. Williams
eClinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta GA, 30341, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yon C. Yu
fEmergency Preparedness and Response Branch, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett W. Petersen
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolle Baird
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Lowe
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Li
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panayampalli S. Satheshkumar
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina L. Hutson
aPoxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background During the 2022 multinational outbreak of monkeypox virus (MPXV) clade IIb, the antiviral drug tecovirimat (TPOXX®) was deployed in the US on a large scale for the first time ever. The MPXV F13L gene homolog encodes the target of tecovirimat, and single amino acid changes in the F13 protein are known to cause resistance to tecovirimat in orthopoxviruses (OPXV).

Methods Whole genome metagenomic sequencing and amplicon-based sequencing targeting the F13L gene was used to identify nine mutations previously reported to cause resistance in other OPXV along with ten novel mutations that have been identified from the 2022 mpox outbreak. A cytopathic effect assay, previously established at CDC as part of WHO smallpox research, was adapted to MPXV for tecovirimat phenotype testing of virus isolated from mpox patients.

Results As of March 2023, in total, 70 isolates from 40 patients were tested, and 50 of these isolates from 26 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of TPOXX treatment; while isolates with F13 mutations identified by routine surveillance of patients not treated with TPOXX have remained sensitive.

Conclusions These data indicate that tecovirimat resistance is developing in immunocompromised patients treated with TPOXX and that for isolates that we have analyzed, the frequency of resistant viruses remain relatively low (< 1%) compared to the total number of patients treated with TPOXX. These findings inform our understanding of when tecovirimat resistance is likely to occur and highlight the need for additional OPXV therapeutics.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The activities in this report were reviewed by the Human Subjects Advisor in the National Center for Emerging and Zoonotic Disease at the Centers for Disease Control and Prevention and determined that it does not meet the regulatory definition of research under provision 45 CFR 46.102(l); the activities fall under public health surveillance and do not require IRB review.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted May 18, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US
Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson
medRxiv 2023.05.16.23289856; doi: https://doi.org/10.1101/2023.05.16.23289856
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Resistance to anti-orthopoxviral drug tecovirimat (TPOXX®) during the 2022 mpox outbreak in the US
Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson
medRxiv 2023.05.16.23289856; doi: https://doi.org/10.1101/2023.05.16.23289856

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)